Jefferies Group LLC reiterated their buy rating on shares of AbbVie Inc (NYSE:ABBV) in a research report released on Friday, Marketbeat Ratings reports. The brokerage currently has a $107.00 price target on the stock, up from their previous price target of $94.00.

A number of other equities research analysts also recently commented on the stock. Piper Jaffray Companies reiterated a buy rating and set a $100.00 price target on shares of AbbVie in a report on Friday. SunTrust Banks, Inc. reiterated a buy rating and set a $95.00 price target on shares of AbbVie in a report on Wednesday, September 13th. Leerink Swann reiterated a market perform rating on shares of AbbVie in a report on Tuesday, September 12th. Cowen and Company reiterated a hold rating and set a $95.00 price target (up from $70.00) on shares of AbbVie in a report on Monday, September 11th. Finally, Goldman Sachs Group, Inc. (The) reiterated a buy rating and set a $100.00 price target (up from $85.00) on shares of AbbVie in a report on Friday, September 8th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $82.38.

Shares of AbbVie (ABBV) opened at 85.32 on Friday. AbbVie has a 52 week low of $55.06 and a 52 week high of $89.69. The stock has a market cap of $136.01 billion, a PE ratio of 20.98 and a beta of 1.48. The company’s 50-day moving average is $75.29 and its 200 day moving average is $69.70.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.02. The business had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. AbbVie had a net margin of 27.58% and a return on equity of 139.57%. The company’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.26 earnings per share. Analysts forecast that AbbVie will post $5.52 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “AbbVie’s (ABBV) Buy Rating Reaffirmed at Jefferies Group LLC” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/19/abbvies-abbv-buy-rating-reaffirmed-at-jefferies-group-llc.html.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be issued a $0.64 dividend. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a yield of 3.00%. AbbVie’s payout ratio is 62.90%.

In other AbbVie news, Chairman Richard A. Gonzalez sold 193,131 shares of AbbVie stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the transaction, the chairman now directly owns 469,623 shares of the company’s stock, valued at $33,343,233. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of AbbVie stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $85.02, for a total transaction of $705,666.00. Following the transaction, the senior vice president now directly owns 93,099 shares in the company, valued at $7,915,276.98. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 373,191 shares of company stock valued at $26,598,305. 0.23% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in ABBV. First Command Financial Services Inc. lifted its position in AbbVie by 6.8% during the first quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock valued at $102,000 after buying an additional 99 shares in the last quarter. Acropolis Investment Management LLC acquired a new position in AbbVie during the second quarter valued at approximately $106,000. Franklin Parlapiano Turner & Welch LLC acquired a new position in AbbVie during the first quarter valued at approximately $108,000. Hudock Capital Group LLC lifted its position in AbbVie by 109.5% during the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after buying an additional 806 shares in the last quarter. Finally, Ffcm LLC lifted its position in AbbVie by 167.2% during the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after buying an additional 963 shares in the last quarter. 68.25% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related stocks with our FREE daily email newsletter.